Latest Mimedx Group Inc (MDXG) Headlines MiMe
Post# of 71
Posted On: 03/10/2014 1:20:25 PM
Latest Mimedx Group Inc (MDXG) Headlines
MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference
PR Newswire - Tue Mar 04, 3:52PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2014 Canaccord|Genuity Musculoskeletal Conference in New Orleans, Louisiana. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, March 11th at 10:00am CDT/11:00am EDT, at the Sheraton New Orleans. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Announces Record 2013 Results
PR Newswire - Wed Feb 26, 6:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the year ended December 31, 2013.
MiMedx Sponsored Osteoarthritis Study Using PURION® Processed Amniotic Tissue Published In Arthritis Research & Therapy
PR Newswire - Tue Feb 25, 7:10PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today a MiMedx-sponsored study from Georgia Institute of Technology has been published in Arthritis Research & Therapy. The article, titled "Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development" was authored by Nick Willett, Tanushree Thote, Angela Lin, Shamus Moran, Yazdan Raji, Sanjay Sridaran, Hazel Stevens and Robert Guldberg. The electronic publication of the study is available at http://arthritis-research.com/content/16/1/R47.
Second MiMedx EpiFix® Randomized Comparative Study Published In International Wound Journal Shows 92.5% Healing Rate Over 12 Weeks
PR Newswire - Tue Feb 25, 6:07PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "A prospective, randomized comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers" has been published electronically in the International Wound Journal. The study manuscript was authored by Charles M. Zelen, DPM, FACFAS; Thomas E. Serena MD, FACS; and Robert J. Snyder, DPM, MSc.
MiMedx EpiFix® Allograft Awarded Coverage by HCSC
PR Newswire - Wed Feb 12, 7:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Health Care Services Corporation (HCSC) has confirmed that the Company's EpiFix® allograft has been awarded reimbursement coverage. HCSC is the largest customer-owned health insurance company in the United States with nearly 14 million members.
RXi Pharmaceuticals Announces Listing on NASDAQ Capital Market
PR Newswire - Tue Feb 11, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that the Company received approval by The NASDAQ Stock Market LLC's ("NASDAQ") Listing Qualification Department to list its common stock on the NASDAQ Capital Market. The Company's common stock will commence trading under the same ticker symbol, "RXII," on the NASDAQ Capital Market effective at the opening of trading on Tuesday, February 11, 2014.
MiMedx EpiFix® Allograft Receives Reimbursement Coverage From The 7th Of The 8 Medicare Contractors
PR Newswire - Mon Feb 10, 8:03AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, Noridian Healthcare Solutions, LLC, has confirmed that the Company's wound care allograft, EpiFix®, has been approved to receive reimbursement coverage.
MiMedx Addresses Misrepresentations In Seeking Alpha Article
PR Newswire - Fri Feb 07, 2:43PM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today issued the following statement regarding a blog post published today on Seeking Alpha.
MiMedx Announces Release Date For 2013 Full Year Results
PR Newswire - Tue Jan 21, 10:08AM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter and year ended December 31, 2013, will be released before the opening of the market on Wednesday, February 26, 2014. MiMedx will host a live broadcast of its fourth quarter and year-end conference call on Wednesday, February 26, 2014 at 10:30am EST. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com or www.earnings.com.
MiMedx to Present at 32nd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 13, 10:23AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced the schedule for its presentation at the 32nd Annual J.P. Morgan Healthcare Conference. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, will present on Thursday, January 16, 2014, 9:00am PST, at the Westin St. Francis Hotel in San Francisco. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
NASA's Destination Station Exhibit Shares The Wonders Of The International Space Station
PR Newswire - Tue Jan 07, 1:41PM CST
OPENS JANUARY 24, 2014 AT THE CALIFORNIA SCIENCE CENTER
Nasdaq stocks posting largest percentage decreases
AP - Mon Jan 06, 12:39PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Accreditations, Stock Price Movements, Reimbursement Coverage, and Conference Presentation Schedules - Research Report on Cigna, CareFusion, Health Management, MiMedx Group, and Merrimack
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Cigna Corp. (NYSE: CI), CareFusion Corporation (NYSE: CFN), Health Management Associates Inc. (NYSE: HMA), MiMedx Group, Inc. (NASDAQ: MDXG), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Pricing of Public Offerings, Agreements, and Stock Movements- Research Report on MiMedx Group, NPS Pharmaceuticals, VIVUS, Merrimack Pharmaceuticals, and GenVec
PR Newswire - Tue Dec 17, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 13, 5:03PM CST
The broad-based S&P 500 may be in the grips of its steepest downtrend in more than five weeks, but that hasn't stopped nearly 45% of companies within The Motley Fool's CAPS database from pushing within 10% of new 52-week highs. For skeptics...
MiMedx (MDXG) in Focus: Stock Moves 13.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 13, 7:25AM CST
MiMedx was a big mover last session, with shares rising nearly 14%.
MiMedx Receives Additional Medicare Reimbursement Coverage for EpiFix®
PR Newswire - Thu Dec 12, 11:27AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, CGS, has confirmed that the Company's wound care allograft, EpiFix®, has received reimbursement coverage from CGS. The coverage by CGS now brings the total Medicare Administrative Contractors (MACs) covering EpiFix® to six of the eight and 86% of Medicare beneficiaries will now be eligible for coverage for EpiFix® products.
MiMedx Prices $34.0 Million Public Offering of Common Stock
PR Newswire - Thu Dec 12, 7:45AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $6.80 per share for gross proceeds of $34.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by MiMedx, will be approximately $31.6 million. The Company has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock to cover over-allotments, if any.
MiMedx Group Announces Proposed Public Offering of Common Stock
PR Newswire - Mon Dec 09, 6:00AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today its intention to offer, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock to cover over-allotments, if any. The proceeds of the offering will be used for continued product development, sales and marketing initiatives and general corporate purposes.
MiMedx Group Inc. (MDXG) is Overbought, What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 06, 4:52AM CST
MiMedx Group Inc. (MDXG) is Overbought, What’s Next?
MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference
PR Newswire - Tue Mar 04, 3:52PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2014 Canaccord|Genuity Musculoskeletal Conference in New Orleans, Louisiana. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, March 11th at 10:00am CDT/11:00am EDT, at the Sheraton New Orleans. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Announces Record 2013 Results
PR Newswire - Wed Feb 26, 6:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the year ended December 31, 2013.
MiMedx Sponsored Osteoarthritis Study Using PURION® Processed Amniotic Tissue Published In Arthritis Research & Therapy
PR Newswire - Tue Feb 25, 7:10PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today a MiMedx-sponsored study from Georgia Institute of Technology has been published in Arthritis Research & Therapy. The article, titled "Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development" was authored by Nick Willett, Tanushree Thote, Angela Lin, Shamus Moran, Yazdan Raji, Sanjay Sridaran, Hazel Stevens and Robert Guldberg. The electronic publication of the study is available at http://arthritis-research.com/content/16/1/R47.
Second MiMedx EpiFix® Randomized Comparative Study Published In International Wound Journal Shows 92.5% Healing Rate Over 12 Weeks
PR Newswire - Tue Feb 25, 6:07PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "A prospective, randomized comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers" has been published electronically in the International Wound Journal. The study manuscript was authored by Charles M. Zelen, DPM, FACFAS; Thomas E. Serena MD, FACS; and Robert J. Snyder, DPM, MSc.
MiMedx EpiFix® Allograft Awarded Coverage by HCSC
PR Newswire - Wed Feb 12, 7:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Health Care Services Corporation (HCSC) has confirmed that the Company's EpiFix® allograft has been awarded reimbursement coverage. HCSC is the largest customer-owned health insurance company in the United States with nearly 14 million members.
RXi Pharmaceuticals Announces Listing on NASDAQ Capital Market
PR Newswire - Tue Feb 11, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that the Company received approval by The NASDAQ Stock Market LLC's ("NASDAQ") Listing Qualification Department to list its common stock on the NASDAQ Capital Market. The Company's common stock will commence trading under the same ticker symbol, "RXII," on the NASDAQ Capital Market effective at the opening of trading on Tuesday, February 11, 2014.
MiMedx EpiFix® Allograft Receives Reimbursement Coverage From The 7th Of The 8 Medicare Contractors
PR Newswire - Mon Feb 10, 8:03AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, Noridian Healthcare Solutions, LLC, has confirmed that the Company's wound care allograft, EpiFix®, has been approved to receive reimbursement coverage.
MiMedx Addresses Misrepresentations In Seeking Alpha Article
PR Newswire - Fri Feb 07, 2:43PM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today issued the following statement regarding a blog post published today on Seeking Alpha.
MiMedx Announces Release Date For 2013 Full Year Results
PR Newswire - Tue Jan 21, 10:08AM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter and year ended December 31, 2013, will be released before the opening of the market on Wednesday, February 26, 2014. MiMedx will host a live broadcast of its fourth quarter and year-end conference call on Wednesday, February 26, 2014 at 10:30am EST. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com or www.earnings.com.
MiMedx to Present at 32nd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 13, 10:23AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced the schedule for its presentation at the 32nd Annual J.P. Morgan Healthcare Conference. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, will present on Thursday, January 16, 2014, 9:00am PST, at the Westin St. Francis Hotel in San Francisco. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
NASA's Destination Station Exhibit Shares The Wonders Of The International Space Station
PR Newswire - Tue Jan 07, 1:41PM CST
OPENS JANUARY 24, 2014 AT THE CALIFORNIA SCIENCE CENTER
Nasdaq stocks posting largest percentage decreases
AP - Mon Jan 06, 12:39PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Accreditations, Stock Price Movements, Reimbursement Coverage, and Conference Presentation Schedules - Research Report on Cigna, CareFusion, Health Management, MiMedx Group, and Merrimack
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Cigna Corp. (NYSE: CI), CareFusion Corporation (NYSE: CFN), Health Management Associates Inc. (NYSE: HMA), MiMedx Group, Inc. (NASDAQ: MDXG), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Pricing of Public Offerings, Agreements, and Stock Movements- Research Report on MiMedx Group, NPS Pharmaceuticals, VIVUS, Merrimack Pharmaceuticals, and GenVec
PR Newswire - Tue Dec 17, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 13, 5:03PM CST
The broad-based S&P 500 may be in the grips of its steepest downtrend in more than five weeks, but that hasn't stopped nearly 45% of companies within The Motley Fool's CAPS database from pushing within 10% of new 52-week highs. For skeptics...
MiMedx (MDXG) in Focus: Stock Moves 13.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 13, 7:25AM CST
MiMedx was a big mover last session, with shares rising nearly 14%.
MiMedx Receives Additional Medicare Reimbursement Coverage for EpiFix®
PR Newswire - Thu Dec 12, 11:27AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, CGS, has confirmed that the Company's wound care allograft, EpiFix®, has received reimbursement coverage from CGS. The coverage by CGS now brings the total Medicare Administrative Contractors (MACs) covering EpiFix® to six of the eight and 86% of Medicare beneficiaries will now be eligible for coverage for EpiFix® products.
MiMedx Prices $34.0 Million Public Offering of Common Stock
PR Newswire - Thu Dec 12, 7:45AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $6.80 per share for gross proceeds of $34.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by MiMedx, will be approximately $31.6 million. The Company has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock to cover over-allotments, if any.
MiMedx Group Announces Proposed Public Offering of Common Stock
PR Newswire - Mon Dec 09, 6:00AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today its intention to offer, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock to cover over-allotments, if any. The proceeds of the offering will be used for continued product development, sales and marketing initiatives and general corporate purposes.
MiMedx Group Inc. (MDXG) is Overbought, What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 06, 4:52AM CST
MiMedx Group Inc. (MDXG) is Overbought, What’s Next?
(0)
(0)MiMedx Group Inc (MDXG) Stock Research Links
Scroll down for more posts ▼